The latest pharma news from Brazil, including Daiichi Sankyo’s new plant; Bristol Myers Squibb’s re-entry into Brazil’s cardiology market; the Anvisa approval of HIV prevention drug, cabotegravir; Merck’s gamble on…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Big Pharma has been raging against the US’s Inflation Reduction Act (IRA) ever since it was passed last year. Merck (MSD global) has recently taken its indignation a step further…
The Saudi Food and Drug Authority (SFDA) has joined the Pharmaceutical Inspection Co-operation Scheme (PIC/S), aimed at harmonising inspection procedures worldwide. Through PIC/S membership the SFDA looks to continue bolstering…
Speaking at the 2023 BIO International Convention Chris Viehbacher who joined Biogen as CEO only a few months ago, criticised the US’s Inflation Reduction Act (IRA), legislation that will allow…
While the COVID-19 pandemic was a global wake-up call for many, life sciences stakeholders argue that not enough is being done to address the rising threats of further health crises…
During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Top stories from Indian pharma including Sanofi India’s plans to demerge its healthcare businesses; Junshi Biosciences and Dr. Reddy’s anti-PD-1 monoclonal antibody partnership; Venus Remedies’ new oncology approvals; CORONA and…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
See our Cookie Privacy Policy Here
